Trade Protagonist Therapeutics Inc - PTGX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.19 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 46.23 |
| Open | 45.15 |
| 1-Year Change | 76.71% |
| Day's Range | 45.15 - 46.77 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 21, 2025 | 45.74 | 0.13 | 0.29% | 45.61 | 46.88 | 45.15 |
| Apr 17, 2025 | 46.23 | 0.62 | 1.36% | 45.61 | 46.67 | 45.61 |
| Apr 16, 2025 | 45.74 | -0.40 | -0.87% | 46.14 | 46.83 | 44.95 |
| Apr 15, 2025 | 46.90 | 2.52 | 5.68% | 44.38 | 48.15 | 44.37 |
| Apr 14, 2025 | 44.94 | 2.10 | 4.90% | 42.84 | 45.42 | 42.32 |
| Apr 11, 2025 | 42.54 | 2.42 | 6.03% | 40.12 | 42.56 | 40.12 |
| Apr 10, 2025 | 40.84 | -1.04 | -2.48% | 41.88 | 42.42 | 39.82 |
| Apr 9, 2025 | 42.51 | 1.67 | 4.09% | 40.84 | 43.68 | 39.51 |
| Apr 8, 2025 | 41.64 | -1.96 | -4.50% | 43.60 | 45.44 | 40.72 |
| Apr 7, 2025 | 43.13 | 0.35 | 0.82% | 42.78 | 45.02 | 42.38 |
| Apr 4, 2025 | 44.39 | -0.55 | -1.22% | 44.94 | 46.24 | 43.85 |
| Apr 3, 2025 | 46.45 | -0.44 | -0.94% | 46.89 | 47.09 | 45.74 |
| Apr 2, 2025 | 48.08 | 1.91 | 4.14% | 46.17 | 48.83 | 46.17 |
| Apr 1, 2025 | 46.82 | -1.02 | -2.13% | 47.84 | 48.61 | 46.41 |
| Mar 31, 2025 | 48.28 | 0.64 | 1.34% | 47.64 | 48.63 | 47.00 |
| Mar 28, 2025 | 48.80 | -0.55 | -1.11% | 49.35 | 50.28 | 48.73 |
| Mar 27, 2025 | 49.39 | 0.34 | 0.69% | 49.05 | 50.44 | 49.05 |
| Mar 26, 2025 | 49.46 | -1.16 | -2.29% | 50.62 | 51.01 | 49.34 |
| Mar 25, 2025 | 51.01 | -1.44 | -2.75% | 52.45 | 52.47 | 50.67 |
| Mar 24, 2025 | 52.55 | -0.71 | -1.33% | 53.26 | 53.40 | 51.54 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Protagonist Therapeutics, Inc. Company profile
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Protagonist Therapeutics Inc revenues decreased 4% to $27.4M. Net loss increased 90% to $125.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 66% to $117M (expense), General and administrative - Balancin increase of 33% to $19.8M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com